The first generation of autoimmune T-cell engagers has demonstrated the power of broad immune-cell depletion, but questions remain around how to achieve deeper, more durable responses while minimizing infection risk, preserving protective immunity, and addressing disease heterogeneity. The next wave of innovation is focused on identifying diseasedriving immune cells, novel targets, and precision immune modulation strategies capable of delivering more selective and effective therapies. Explore how the field can move beyond conventional approaches by:

• Identifying the optimal pathogenic immune-cell populations to target, evaluating advances in target discovery, immune repertoire profiling, and disease biology to distinguish disease-driving cells from healthy immune populations and improve therapeutic selectivity
• Advancing multi-specific and precision immune modulation strategies, discussing how trispecific, logic-gated, and nextgeneration immune engager platforms can enhance specificity, overcome antigen heterogeneity, and deliver deeper and more durable disease control
• Balancing efficacy, safety, and immune preservation, exploring how novel targeting approaches can achieve potent depletion of pathogenic cells while minimizing off-target toxicity, reducing infection risk, and preserving long-term immune competence